Abera Bioscience AB
Research Abera Bioscience AB (ABERA.ST) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerABERA.ST
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Financial periodQ2 2026
- RevenueSEK 0
- Net income-SEK 5.56M
- Free cash flow-SEK 8.33M
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 10.45M | -SEK 3.68M | n/a | -0.57 | SEK 23.49M | n/a | SEK 19.29M |
About Abera Bioscience AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Abera Bioscience AB do?
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis.